{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:17:50Z","timestamp":1791598670797,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003213","name":"Beijing Municipal Education Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003213","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.lungcan.2020.09.012","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T20:07:16Z","timestamp":1600978036000},"page":"154-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer"],"prefix":"10.1016","volume":"149","author":[{"given":"Hong","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoxue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanying","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.09.012_bib0005","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0015","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1200\/JCO.2009.23.6661","article-title":"EML4-ALK: honing in on a new target in non-small-cell lung cancer","volume":"27","author":"Horn","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11523-019-00631-x","article-title":"Distribution of ALK fusion variants and correlation with clinical outcomes in Chinese patients with non-small cell lung cancer treated with Crizotinib","volume":"14","author":"Su","year":"2019","journal-title":"Target. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0025","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0030","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0035","doi-asserted-by":"crossref","first-page":"21903","DOI":"10.18632\/oncotarget.15746","article-title":"Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study","volume":"8","author":"Duruisseaux","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/JTO.0000000000000030","article-title":"Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays","volume":"9","author":"Li","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0045","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/COC.0000000000000508","article-title":"Anaplastic lymphoma kinase (ALK)-positive tumors: clinical, radiographic and molecular profiles, and uncommon sites of metastases in patients with lung adenocarcinoma","volume":"42","author":"Gupta","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0050","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.lungcan.2018.01.026","article-title":"Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants","volume":"118","author":"Li","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0055","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer","volume":"34","author":"Yoshida","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0060","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/ijc.31275","article-title":"EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer","volume":"142","author":"Christopoulos","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0065","doi-asserted-by":"crossref","first-page":"e1070","DOI":"10.1634\/theoncologist.2018-0572","article-title":"Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer","volume":"24","author":"Wen","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0070","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mds626","article-title":"Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages","volume":"24","author":"Zhou","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0075","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/gcc.22198","article-title":"ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients","volume":"53","author":"Tuononen","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0080","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.21037\/jtd.2018.05.131","article-title":"Anaplastic lymphoma kinase rearrangement in surgically resected stage IA lung adenocarcinoma","volume":"10","author":"Shin","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0085","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jjco\/hyw094","article-title":"Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer","volume":"46","author":"Mizuno","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0090","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.21037\/jtd.2019.09.65","article-title":"Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma","volume":"11","author":"Liu","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0095","first-page":"93","article-title":"The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0100","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jtho.2017.11.117","article-title":"Evaluation of NGS and RT-PCR methods for ALK rearrangement in european NSCLC patients: results from the european thoracic oncology platform lungscape project","volume":"13","author":"Letovanec","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0110","first-page":"70","article-title":"Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements","volume":"3","author":"Teixid\u00f3","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0115","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/COC.0000000000000213","article-title":"Diagnosis of EML4-ALK translocation with FISH, immunohistochemistry, and real-time polymerase chain reaction in patients with non-small cell lung cancer","volume":"40","author":"Cruz-Rico","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0120","doi-asserted-by":"crossref","first-page":"E3939","DOI":"10.3390\/ijms20163939","article-title":"Fluorescence in Situ Hybridization (FISH) for detecting anaplastic lymphoma kinase (ALK) rearrangement in lung cancer: clinically relevant technical aspects","volume":"20","author":"Tang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0125","doi-asserted-by":"crossref","first-page":"495","DOI":"10.21147\/j.issn.1000-9604.2016.05.04","article-title":"Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center large-scale investigation of 1, 504 Chinese Han patients","volume":"28","author":"Yang","year":"2016","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0130","doi-asserted-by":"crossref","first-page":"560","DOI":"10.21037\/tlcr.2017.08.03","article-title":"Molecular diagnostics of lung cancer in the clinic","volume":"6","author":"Sholl","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2018.05.020","article-title":"Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer","volume":"122","author":"Chaft","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0140","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.7150\/jca.36580","article-title":"Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non-small cell lung cancer","volume":"11","author":"Lu","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0145","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1111\/cas.14177","article-title":"Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer","volume":"110","author":"Zhou","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0150","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/1759-7714.12395","article-title":"Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma","volume":"8","author":"Tao","year":"2017","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0155","first-page":"436","article-title":"Clinicopathological features of lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements","volume":"37","author":"Dong","year":"2015","journal-title":"Chin. J. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7150\/jca.26947","article-title":"Comparison of clinicopathological features and prognosis between ALK rearrangements and EGFR mutations in surgically resected early-stage lung adenocarcinoma","volume":"10","author":"Li","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0165","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0170","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ijc.31893","article-title":"Identification of a highly lethal V3 + TP53 + subset in ALK + lung adenocarcinoma","volume":"144","author":"Christopoulos","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0175","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0180","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/j.cllc.2017.04.006","article-title":"Coexistence of EGFR, KRAS, BRAF, and PIK3CA mutations and ALK rearrangement in a comprehensive cohort of 326 consecutive Spanish nonsquamous NSCLC patients","volume":"18","author":"Mart\u00edn Martorell","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.09.012_bib0185","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/1078-0432.CCR-17-2289","article-title":"The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the lung cancer mutation consortium (LCMC2)","volume":"24","author":"Aisner","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.09.012_bib0190","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10555-015-9592-y","article-title":"Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?","volume":"34","author":"Toyokawa","year":"2015","journal-title":"Cancer Metastasis Rev."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022030622X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022030622X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:47:52Z","timestamp":1759236472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022030622X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":38,"alternative-id":["S016950022030622X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.09.012","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}